Compound

apixaban

CHEBI:72296ChEBI

Open in the graph

Studied for

2 endpoints · 2 findings · 1 paper · 2 null

All-cause mortalityno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Incidence of strokeno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.

Every finding, with the quotes

What the evidence says

How to read these marks

2 findings · 2 endpoints · 1 paper · 2 null · by evidence strength

Heavier lines are better evidence, and a line with a gap in the middle is an inference rather than a reported result. Two lines arriving at one endpoint are two findings of it, marked ×2. How evidence strength is computed.

Every finding here is a null result.

What did not

2 findings

No detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“When the cardiovascular outcomes were assessed, no significant change was observed in all-cause mortality (OR: 1.12, 95% CI: 0.89–1.40; P =.33), MACEs (OR: 0.96, 95% CI: 0.82–1.14; P =.67), stroke (OR: 0.73, 95% CI: 0.44–1.20; P =.22), stent thrombosis (OR: 0.72, 95% CI: 0.47–1.12; P =.15), and MI (OR: 0.92, 95% CI: 0.75–1.13; P =.44) when apixaban was added to DAPT as shown in Figure 4.”
Quoted verbatim from Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis..
Study

meta-analysis
Population

Patients with acute coronary syndrome, pooled across 4 RCTs; apixaban plus aspirin and clopidogrel (DAPT) versus DAPT alone
Effect 1.12 odds ratio, 95% CI 0.89 to 1.4
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.2021PMID:33761699Permalink
No detected effect on incidence of stroke
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“When the cardiovascular outcomes were assessed, no significant change was observed in all-cause mortality (OR: 1.12, 95% CI: 0.89–1.40; P =.33), MACEs (OR: 0.96, 95% CI: 0.82–1.14; P =.67), stroke (OR: 0.73, 95% CI: 0.44–1.20; P =.22), stent thrombosis (OR: 0.72, 95% CI: 0.47–1.12; P =.15), and MI (OR: 0.92, 95% CI: 0.75–1.13; P =.44) when apixaban was added to DAPT as shown in Figure 4.”
Quoted verbatim from Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis..
Study

meta-analysis
Population

Patients with acute coronary syndrome, pooled across 4 RCTs; apixaban plus aspirin and clopidogrel (DAPT) versus DAPT alone
Effect 0.73 odds ratio, 95% CI 0.44 to 1.2
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.2021PMID:33761699Permalink

Papers screened

498 papers

Compound: apixaban
Screened: 498
Admitted: 1
Discarded: 11
Not read: 486
Showing: 200 of 498

The whole record

Produced a finding1 paper

PMID:337616992026-10-05

Discarded: no comparator8 papers

PMID:26716830no claim extracted — comparator_not_absence2026-10-05
PMID:27487187no claim extracted — comparator_not_absence2026-10-05
PMID:30341244no claim extracted — comparator_not_absence2026-10-05
PMID:31405948no claim extracted — comparator_not_absence2026-10-05
PMID:31918558no claim extracted — comparator_not_absence2026-10-05
PMID:35801133no claim extracted — comparator_not_absence2026-10-05
PMID:37893585no claim extracted — comparator_not_absence2026-10-05
PMID:38770962no claim extracted — comparator_not_absence2026-10-05

Discarded: another reason, stated per paper3 papers

PMID:24617578no claim extracted — cause not determined (one pass only) — measured: adverse coronary events, composite of acute coronary syndrome or myocardial infarction, pooled odds ratio2026-10-05
PMID:29195825no claim extracted — cause not determined2026-10-05
PMID:31527894no claim extracted — design_has_no_evidence_type2026-10-05

Not read yet486 papers

PMID:254871642026-09-29
PMID:257287542026-09-29
PMID:262131782026-09-29
PMID:262586732026-09-29
PMID:262929592026-09-29
PMID:262984482026-09-29
PMID:264393232026-09-29
PMID:264640272026-09-29
PMID:268035502026-09-29
PMID:270718192026-09-29
PMID:270916862026-09-29
PMID:272464502026-09-29

and 474 more.

Measured, not recorded

Compound: apixaban
Endpoints measured: 259 endpoints
Recorded as a finding: No

Show what was measured

adverse coronary events (acute coronary syndrome or myocardial infarction): apixaban vs control (placebo, heparin or vitamin K antagonist pooled) and adjusted indirect comparison vs dabigatran (abstract only)
apixaban pooled OR 0.89, 95% CI 0.78, 1.03
Not recorded as a finding: the comparison was against another active treatment
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93).
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction composite), pooled odds ratio of apixaban vs control (placebo, heparin or vitamin K antagonist), plus adjusted indirect comparison vs dabigatran (abstract only)
apixaban pooled OR 0.89, 95% CI 0.78, 1.03
Not recorded as a finding: this platform holds no node for the endpoint
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93).
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
no effect
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93)
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Overall, adjusted indirect comparison suggested that both apixaban (OR 0.61, 95% CI 0.44, 0.85) and rivaroxaban (OR 0.54; 95% CI 0.39, 0.76) were associated with lower coronary risk than dabigatran
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Restricting the indirect comparison to a vitamin K antagonist as a common control, yielded similar findings, OR 0.57 (95% CI 0.39, 0.85) for apixaban vs. dabigatran and 0.53 (95% CI 0.37, 0.77) for rivaroxaban vs. dabigatran
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
increases
Dabigatran was associated with a significantly increased risk of adverse coronary events in pooled analysis of nine trials (OR 1.45, 95% CI 1.14, 1.86)
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93)
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Overall, adjusted indirect comparison suggested that both apixaban (OR 0.61, 95% CI 0.44, 0.85) and rivaroxaban (OR 0.54; 95% CI 0.39, 0.76) were associated with lower coronary risk than dabigatran
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Restricting the indirect comparison to a vitamin K antagonist as a common control, yielded similar findings, OR 0.57 (95% CI 0.39, 0.85) for apixaban vs. dabigatran and 0.53 (95% CI 0.37, 0.77) for rivaroxaban vs. dabigatran
PMID:24617578 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
CRNM bleeding
no effect
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
CRNM bleeding
increases
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
CRNM bleeding
increases
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
increases
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death, major bleeding, CRNM bleeding, all-cause mortality in initial/long-term VTE treatment; network meta-analysis of apixaban vs warfarin/VKA, rivaroxaban, dabigatran and edoxaban
Not recorded as a finding: the comparison was against another active treatment
Our analysis shows a similar efficacy on mortality for the NOACs compared with conventional therapy, with apixaban being the only NOAC to show a significantly improved bleeding profile for all reported measures.
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death, major or clinically relevant non-major bleeding, all-cause mortality: apixaban vs enoxaparin/warfarin (VKA) and vs other NOACs in initial and long-term VTE treatment, Bayesian network meta-analysis relative risks
decreases
Not recorded as a finding: the comparison was against another active treatment
With regard to a head-to-head comparison of the NOACs, apixaban was associated with a significantly lower risk of ‘major or CRNM bleeding’ compared with dabigatran, edoxaban, or rivaroxaban.
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
CRNM bleeding
decreases
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
major bleeding
decreases
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
major bleeding
decreases
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
increases
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death, major bleeding, clinically relevant non-major bleeding, all-cause mortality in extended VTE treatment; fixed-effect Bayesian network meta-analysis of apixaban vs rivaroxaban, dabigatran, aspirin and warfarin
no effect, no statistically significant differences between any treatments in all-cause mortality
Not recorded as a finding: the comparison was against another active treatment
There were no other statistically significant differences between the NOACs for the outcomes reported in Table 2, and no statistically significant differences between any treatments in terms of all-cause mortality.
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death, major or clinically relevant non-major bleeding, all-cause mortality: apixaban vs warfarin, aspirin, rivaroxaban and dabigatran in extended VTE treatment, Bayesian network meta-analysis relative risks
decreases
Not recorded as a finding: the comparison was against another active treatment
Apixaban was the only NOAC to show a significantly lower risk of bleeding compared with warfarin INR 2.0–3.0 using all three outcome measures.
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
decreases
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
increases
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
decreases
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
decreases
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
clinically significant bleeding (ISTH/TIMI composite) and MACE (MI, stroke, all-cause mortality composite) when NOACs (apixaban, rivaroxaban, dabigatran pooled) were added to single or dual antiplatelet therapy in ACS
NOAC plus DAPT: bleeding HR 2.24, 95% CI 1.75 to 2.87; MACE HR 0.86, 95% CI 0.78 to 0.93
Not recorded as a finding: another reason, stated per paper
Conversely, a modest reduction in MACE was achieved when NOAC was combined with DAPT (HR 0.86, 95% CI 0.78 to 0.93, p < 0.001); however, this strategy more than doubled the risk of bleeding (HR 2.24, 95% CI 1.75 to 2.87, p < 0.001).
PMID:29195825 · one of two readings recorded this
clinically significant bleeding
increases, p = 0.001
this strategy more than doubled the risk of bleeding (HR 2.24, 95% CI 1.75 to 2.87, p < 0.001)
PMID:29195825 · one of two readings recorded this
clinically significant bleeding
no effect, p = 0.31, n = 31574
In 31,574 patients, addition of NOAC to SAP did not increase the risk of clinically significant bleeding (HR 0.82, 95% CI 0.56 to 1.20, p = 0.31)
PMID:29195825 · one of two readings recorded this
clinically significant bleeding
decreases, p = 0.001
dabigatran plus SAP was a safer approach compared with control (HR 0.51, 95% CI 0.42 to 0.61, p < 0.001)
PMID:29195825 · one of two readings recorded this
MACE (myocardial infarction, stroke, all-cause mortality)
decreases, p = 0.001
a modest reduction in MACE was achieved when NOAC was combined with DAPT (HR 0.86, 95% CI 0.78 to 0.93, p < 0.001)
PMID:29195825 · one of two readings recorded this
MACE (myocardial infarction, stroke, all-cause mortality)
no effect, p = 0.1
also lacked the beneficial effect on MACE (HR 0.82, 95% CI 0.66 to 1.04, p = 0.10)
PMID:29195825 · one of two readings recorded this
MACE (myocardial infarction, stroke, all-cause mortality)
decreases
only rivaroxaban plus DAPT showed significant 17% reduction in MACE
PMID:29195825 · one of two readings recorded this
publication bias, Egger test, clinically significant bleeding
no effect, p = 0.75
Egger test did not highlight publication bias for clinically significant bleeding (2-tailed p = 0.75)
PMID:29195825 · one of two readings recorded this
publication bias, Egger test, MACE
no effect, p = 0.5
or MACE (2-tailed p = 0.50)
PMID:29195825 · one of two readings recorded this
bleeding events (major and clinically relevant non-major)
no effect, p = 0.05
Similar results were obtained in apixaban groups 4.09% (228/5570) compared with the control groups 4.64 (265/5755) that were all enoxaparin, indicating that no significant difference was observed in bleeding events of the two drugs (RR 0.85, 95% CI 0.71–1.02), P>0.05
PMID:30341244 · one of two readings recorded this
bleeding events (major and clinically relevant non-major)
no effect, p = 0.05
However, the effect was not significant (RR 0.69, 95% CI 0.42–1.12), P>0.05
PMID:30341244 · one of two readings recorded this
bleeding events (major and clinically relevant non-major)
no effect, p = 0.05
This result suggested that rivaroxaban may have a trend to increase the bleeding events compared with enoxaparin; however, the difference is not significant (RR 1.18, 95% CI 0.95–1.47), P>0.05
PMID:30341244 · one of two readings recorded this
composite of DVT, non-fatal pulmonary embolism and all-cause mortality, and bleeding events (major plus clinically relevant non-major), after hip or knee arthroplasty; apixaban vs enoxaparin
no effect, efficacy RR 0.59, 95% CI 0.34-1.02
Not recorded as a finding: the comparison was against another active treatment
The efficacy outcome of apixaban groups didn’t show significant difference compared with the control groups (RR 0.59, 95% CI 0.34-1.02), P>0.05.
PMID:30341244 · one of two readings recorded this
composite of DVT, non-fatal pulmonary embolism and all-cause mortality, and bleeding events (major plus clinically relevant non-major): apixaban vs enoxaparin after total hip or knee arthroplasty, pooled odds/risk ratios
no effect, apixaban vs enoxaparin efficacy composite RR 0.59, 95% CI 0.34-1.02
Not recorded as a finding: the comparison was against another active treatment
The efficacy outcome of apixaban groups didn’t show significant difference compared with the control groups (RR 0.59, 95% CI 0.34-1.02), P>0.05.
PMID:30341244 · one of two readings recorded this
primary efficacy composite (DVT, non-fatal pulmonary embolism, all-cause mortality)
no effect, p = 0.05
The efficacy outcome of apixaban groups didn’t show significant difference compared with the control groups (RR 0.59, 95% CI 0.34-1.02), P>0.05
PMID:30341244 · one of two readings recorded this
primary efficacy composite (DVT, non-fatal pulmonary embolism, all-cause mortality)
increases, p = 0.05
Results showed that events occurred in 11.03% patients (1919/17,397) of enoxaparin groups compared with 8.38% patients (1582/18,889) of the control groups, indicating that enoxaparin had a trend to increase the events (RR 1.56, 95% CI 1.20-2.04), P<0.05
PMID:30341244 · one of two readings recorded this
primary efficacy composite (DVT, non-fatal pulmonary embolism, all-cause mortality)
decreases, p = 0.0001
Total events occurred in 4.89% (509/10399) patients in rivaroxaban group compared with 9.55% (976/10221) patients in the control group, indicating rivaroxaban had a trend to decrease the events (RR 0.46, 95% CI 0.41-0.51), P<0.0001
PMID:30341244 · one of two readings recorded this
clinically relevant major bleeding
decreases, p = 0.01
Clinically relevant major bleeding occurred in 85 of 11 559 patients (0.74%) in the apixaban group and 350 of 33 909 patients (1.03%) in the rivaroxaban group (RR, 0.73; 95% CI, 0.58-0.93; P = .01)
PMID:31405948 · one of two readings recorded this
clinically relevant nonmajor bleeding
decreases, p = 0.01
Clinically relevant nonmajor bleeding occurred in 169 of 3417 patients (4.95%) in the apixaban group and 1094 of 12 475 patients (8.77%) in the rivaroxaban group (RR, 0.59; 95% CI, 0.50-0.70; P < .01)
PMID:31405948 · one of two readings recorded this
recurrent VTE within 6 months, clinically relevant major bleeding, clinically relevant non-major bleeding; apixaban vs rivaroxaban in acute VTE, real-world studies (abstract only)
no effect, recurrent VTE RR 0.89; 95% CI 0.67-1.19, p = 0.45
Not recorded as a finding: the comparison was against another active treatment
In an analysis involving 24 041 patients, recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45).
PMID:31405948 · one of two readings recorded this
recurrent VTE within 6 months, clinically relevant major bleeding, clinically relevant nonmajor bleeding: apixaban vs rivaroxaban in acute VTE, pooled risk ratios from real-world studies (abstract only)
recurrent VTE RR 0.89, 95% CI 0.67-1.19, p = 0.45
Not recorded as a finding: the comparison was against another active treatment
In an analysis involving 24 041 patients, recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45).
PMID:31405948 · one of two readings recorded this
recurrent VTE
no effect, p = 0.45
recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45)
PMID:31405948 · one of two readings recorded this
cost per LY gained
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Dabigatran (150 mg) | €1,959 | 0.008 | €244,079 | 0.022 | €90,398
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Edoxaban | €13 | 0.065 | €206 | 0.085 | €157
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Edoxaban | €186 | 0.065 | €2,884 | 0.085 | €2,193
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Edoxaban | €385 | 0.038 | €10,243 | 0.055 | €6,951
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €1,518 | 0.262 | €5,787 | 0.269 | €5,636
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €1,390 | 0.246 | €5,648 | 0.249 | €5,580
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €96 | 0.330 | €292 | 0.352 | €273
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Dabigatran (110mg) | - €2,692 | 0.177 | Dominant | 0.207 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Dabigatran (150 mg) | - €819 | 0.131 | Dominant | 0.157 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Dabigatran | - €3,612 | 0.310 | Dominant | 0.383 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Edoxaban | - €197 | 0.065 | Dominant | 0.085 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Rivaroxaban | - €1,027 | 0.101 | Dominant | 0.126 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Rivaroxaban | - €1,625 | 0.124 | Dominant | 0.154 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
increases
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
VKA | - €1,358 | 0.330 | Dominant | 0.352 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Dabigatran (110mg) | - €2,692 | 0.177 | Dominant | 0.207 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Dabigatran (150 mg) | - €819 | 0.131 | Dominant | 0.157 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Dabigatran | - €3,612 | 0.310 | Dominant | 0.383 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Edoxaban | - €197 | 0.065 | Dominant | 0.085 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Rivaroxaban | - €1,027 | 0.101 | Dominant | 0.126 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Rivaroxaban | - €1,625 | 0.124 | Dominant | 0.154 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
incremental LY
increases
VKA | - €1,358 | 0.330 | Dominant | 0.352 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Dabigatran (110mg) | - €2,692 | 0.177 | Dominant | 0.207 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Dabigatran (150 mg) | - €819 | 0.131 | Dominant | 0.157 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Dabigatran | - €3,612 | 0.310 | Dominant | 0.383 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Edoxaban | - €197 | 0.065 | Dominant | 0.085 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Rivaroxaban | - €1,027 | 0.101 | Dominant | 0.126 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Rivaroxaban | - €1,625 | 0.124 | Dominant | 0.154 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
VKA | - €1,358 | 0.330 | Dominant | 0.352 | Dominant
PMID:31527894 · one of two readings recorded this
probability of being the most cost-effective option at the WTP threshold
In NMA-based analysis, apixaban is the most cost-effective treatment option at the €20,000/QALY WTP threshold with 50%
PMID:31527894 · one of two readings recorded this
probability of being the most cost-effective option at the WTP threshold
In RWD-based analysis, similar results were found: apixaban is the most cost-effective treatment with 90%
PMID:31527894 · one of two readings recorded this
hemorrhagic stroke
no effect
A numerical difference was found that was suggestive of a potential benefit of apixaban in reducing the risk of hemorrhagic stroke in all 7 NMAs
PMID:31918558 · one of two readings recorded this
hemorrhagic stroke
no effect
Two RWE studies demonstrated a numerical, but nonsignificant difference in favor of apixaban (HR: 0.66, 95% CI: 0.16-2.78; HR: 0.87, 95% CI: 0.50-1.53), and one RWE study favored rivaroxaban (HR: 1.09, 95% CI: 0.89-1.33)
PMID:31918558 · one of two readings recorded this
hemorrhagic stroke
no effect
Two RWE studies demonstrated a numerical, but nonsignificant difference in favor of apixaban (HR: 0.66, 95% CI: 0.16-2.78; HR: 0.87, 95% CI: 0.50-1.53), and one RWE study favored rivaroxaban (HR: 1.09, 95% CI: 0.89-1.33)
PMID:31918558 · one of two readings recorded this
hemorrhagic stroke
no effect
Two RWE studies demonstrated a numerical, but nonsignificant difference in favor of apixaban (HR: 0.66, 95% CI: 0.16-2.78; HR: 0.87, 95% CI: 0.50-1.53), and one RWE study favored rivaroxaban (HR: 1.09, 95% CI: 0.89-1.33)
PMID:31918558 · one of two readings recorded this
ischemic stroke
no effect
No differences were observed for the outcome of ischemic stroke as indicated by the NMAs
PMID:31918558 · one of two readings recorded this
ischemic stroke
decreases
one reported a statistically significant difference in favor of apixaban (HR: 0.67, 95% CI: 0.49-0.92); the other reported a numerical difference in favor of rivaroxaban which was nonsignificant (HR: 1.27, 95% CI: 0.73-2.23)
PMID:31918558 · one of two readings recorded this
ischemic stroke
no effect
one reported a statistically significant difference in favor of apixaban (HR: 0.67, 95% CI: 0.49-0.92); the other reported a numerical difference in favor of rivaroxaban which was nonsignificant (HR: 1.27, 95% CI: 0.73-2.23)
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
These demonstrated results similar to the main analysis (apixaban 2.5 mg or 5 mg) for the outcome of major bleeding (HR: 0.41, 95% CI: 0.29-0.56 and 0.56, 95% CI: 0.41-0.78, respectively)
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
These demonstrated results similar to the main analysis (apixaban 2.5 mg or 5 mg) for the outcome of major bleeding (HR: 0.41, 95% CI: 0.29-0.56 and 0.56, 95% CI: 0.41-0.78, respectively)
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
All 5 RWE studies reported major bleeding, with all demonstrating a statistically significant advantage in favor of apixaban
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
Sixteen of the 21 NMAs reported apixaban had a significantly lower risk of major bleeding compared with rivaroxaban
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism, ischemic and hemorrhagic stroke, ISTH major bleeding: apixaban vs rivaroxaban in nonvalvular atrial fibrillation, narrated across network meta-analyses and real-world cohort studies, no pooling
decreases, major bleeding, apixaban vs rivaroxaban, NMA HR range 0.51-0.74
Not recorded as a finding: the comparison was against another active treatment
Sixteen of the 21 NMAs reported apixaban had a significantly lower risk of major bleeding compared with rivaroxaban, with the other 5 demonstrating a numerical difference in favor of apixaban (HR: 0.51-0.74; OR: 0.19-0.71; RR: 0.68-0.80; Figure 3).
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
no effect
Results from 15 of 21 NMAs examining stroke/systemic embolism showed that apixaban and rivaroxaban had a comparable efficacy profile in terms of preventing the stroke/systemic embolism risk
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
decreases
one study, including only AF patients >65 years of age, demonstrated a statistically significant advantage for apixaban compared to rivaroxaban in the reduction of stroke/systemic embolism risk (HR: 0.72, 95% CI: 0.55-0.95)
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
no effect
favored rivaroxaban in a dose-adjusting sensitivity analysis that included both the reduced (2.5 mg) and standard dose (main analyses; HR: 1.11, 95% CI: 0.68-1.81)
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
no effect
The second study found comparable results between the 2 interventions (HR: 1.05, 95% CI: 0.64-1.72)
PMID:31918558 · one of two readings recorded this
all-cause mortality
no effect, p = 0.33
All-cause mortality | 1.12 [0.89–1.40] |.33
PMID:33761699 · one of two readings recorded this
any bleeding event
increases, p = 0.0007
Any bleeding event | 1.91 [1.31–2.77] |.0007
PMID:33761699 · one of two readings recorded this
fatal bleeding
no effect, p = 0.11
Fatal bleeding | 10.96 [0.61–198.3] |.11
PMID:33761699 · one of two readings recorded this
GUSTO defined severe bleeding
increases, p = 0.01
GUSTO defined severe bleeding | 3.00 [1.56–5.78] |.01
PMID:33761699 · one of two readings recorded this
ISTH defined minor bleeding
no effect, p = 0.08
ISTH defined minor bleeding | 2.33 [0.91–5.96] |.08
PMID:33761699 · one of two readings recorded this
ISTH major bleeding
increases, p = 0.00001
ISTH major bleeding | 2.49 [1.80–3.45] |.00001
PMID:33761699 · one of two readings recorded this
major adverse cardiac events (MACEs)
no effect, p = 0.67
MACEs | 0.96 [0.82–1.14] |.67
PMID:33761699 · one of two readings recorded this
myocardial infarction (MI)
no effect, p = 0.44
MI | 0.92 [0.75–1.13] |.44
PMID:33761699 · one of two readings recorded this
stent thrombosis
no effect, p = 0.15
Stent thrombosis | 0.72 [0.47–1.12] |.15
PMID:33761699 · one of two readings recorded this
stroke
no effect, p = 0.22
Stroke | 0.73 [0.44–1.20] |.22
PMID:33761699 · one of two readings recorded this
TIMI defined major bleeding
increases, p = 0.0008
TIMI defined major bleeding | 2.45 [1.45–4.12] |.0008
PMID:33761699 · one of two readings recorded this
TIMI defined minor bleeding
increases, p = 0.0002
TIMI defined minor bleeding | 3.12 [1.71–5.70] |.0002
PMID:33761699 · one of two readings recorded this
all-cause mortality
no effect
Meta-analysis of studies assessing API did not demonstrate significant differences versus SoC in either of the feasible scenarios but point estimates in favor of API
PMID:35801133 · one of two readings recorded this
all-cause mortality
decreases
A meta-analysis of all studies revealed that RIV was associated with a significantly lower risk of death compared with SoC (HR = 0.56 (0.39, 0.80))
PMID:35801133 · one of two readings recorded this

The whole record — 259 rows

Sources cited

1 paper

Subject: apixaban
Findings: 2
Papers: 1

Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.record2021PMID:337616992 findings

Measured, not recorded

Compound

apixaban

Endpoints measured

259 endpoints

Recorded as a finding

Show what was measured

adverse coronary events (acute coronary syndrome or myocardial infarction): apixaban vs control (placebo, heparin or vitamin K antagonist pooled) and adjusted indirect comparison vs dabigatran (abstract only)
apixaban pooled OR 0.89, 95% CI 0.78, 1.03
Not recorded as a finding: the comparison was against another active treatment
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93).
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction composite), pooled odds ratio of apixaban vs control (placebo, heparin or vitamin K antagonist), plus adjusted indirect comparison vs dabigatran (abstract only)
apixaban pooled OR 0.89, 95% CI 0.78, 1.03
Not recorded as a finding: this platform holds no node for the endpoint
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93).
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
no effect
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93)
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Overall, adjusted indirect comparison suggested that both apixaban (OR 0.61, 95% CI 0.44, 0.85) and rivaroxaban (OR 0.54; 95% CI 0.39, 0.76) were associated with lower coronary risk than dabigatran
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Restricting the indirect comparison to a vitamin K antagonist as a common control, yielded similar findings, OR 0.57 (95% CI 0.39, 0.85) for apixaban vs. dabigatran and 0.53 (95% CI 0.37, 0.77) for rivaroxaban vs. dabigatran
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
increases
Dabigatran was associated with a significantly increased risk of adverse coronary events in pooled analysis of nine trials (OR 1.45, 95% CI 1.14, 1.86)
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
There was no signal for coronary risk with apixaban from nine trials (pooled OR 0.89, 95% CI 0.78, 1.03) or rivaroxaban from nine trials (pooled OR 0.81, 95% CI 0.72, 0.93)
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Overall, adjusted indirect comparison suggested that both apixaban (OR 0.61, 95% CI 0.44, 0.85) and rivaroxaban (OR 0.54; 95% CI 0.39, 0.76) were associated with lower coronary risk than dabigatran
PMID:24617578 · one of two readings recorded this
adverse coronary events (acute coronary syndrome or myocardial infarction)
decreases
Restricting the indirect comparison to a vitamin K antagonist as a common control, yielded similar findings, OR 0.57 (95% CI 0.39, 0.85) for apixaban vs. dabigatran and 0.53 (95% CI 0.37, 0.77) for rivaroxaban vs. dabigatran
PMID:24617578 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
CRNM bleeding
no effect
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
CRNM bleeding
decreases
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
CRNM bleeding
increases
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
CRNM bleeding
increases
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
major bleeding
decreases
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
decreases
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
increases
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death, major bleeding, CRNM bleeding, all-cause mortality in initial/long-term VTE treatment; network meta-analysis of apixaban vs warfarin/VKA, rivaroxaban, dabigatran and edoxaban
Not recorded as a finding: the comparison was against another active treatment
Our analysis shows a similar efficacy on mortality for the NOACs compared with conventional therapy, with apixaban being the only NOAC to show a significantly improved bleeding profile for all reported measures.
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death, major or clinically relevant non-major bleeding, all-cause mortality: apixaban vs enoxaparin/warfarin (VKA) and vs other NOACs in initial and long-term VTE treatment, Bayesian network meta-analysis relative risks
decreases
Not recorded as a finding: the comparison was against another active treatment
With regard to a head-to-head comparison of the NOACs, apixaban was associated with a significantly lower risk of ‘major or CRNM bleeding’ compared with dabigatran, edoxaban, or rivaroxaban.
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. dabigatran | 0.76 | 0.69 | 0.40 | 0.80 | 0.79
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. edoxaban | 1.01 | 0.54 | 0.36 | 0.59 | 0.75
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. rivaroxaban | 0.93 | 0.47 | 0.55 | 0.47 | 0.82
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban vs. VKA | 0.83 | 0.44 | 0.30 | 0.48 | 0.79
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Dabigatran vs. edoxaban | 1.32 | 0.77 | 0.89 | 0.74 | 0.95
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Dabigatran vs. VKA | 1.09 | 0.64 | 0.76 | 0.60 | 1.00
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Edoxaban vs. VKA | 0.83 | 0.82 | 0.85 | 0.81 | 1.05
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban vs. dabigatran | 0.82 | 1.48 | 0.73 | 1.70 | 0.96
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban vs. edoxaban | 1.09 | 1.14 | 0.65 | 1.26 | 0.92
PMID:26716830 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban vs. VKA | 0.90 | 0.94 | 0.55 | 1.02 | 0.96
PMID:26716830 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
all-cause mortality
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
CRNM bleeding
decreases
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
major bleeding
decreases
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
major bleeding
decreases
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
major bleeding
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
decreases
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
increases
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
major or CRNM bleeding
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death, major bleeding, clinically relevant non-major bleeding, all-cause mortality in extended VTE treatment; fixed-effect Bayesian network meta-analysis of apixaban vs rivaroxaban, dabigatran, aspirin and warfarin
no effect, no statistically significant differences between any treatments in all-cause mortality
Not recorded as a finding: the comparison was against another active treatment
There were no other statistically significant differences between the NOACs for the outcomes reported in Table 2, and no statistically significant differences between any treatments in terms of all-cause mortality.
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death, major or clinically relevant non-major bleeding, all-cause mortality: apixaban vs warfarin, aspirin, rivaroxaban and dabigatran in extended VTE treatment, Bayesian network meta-analysis relative risks
decreases
Not recorded as a finding: the comparison was against another active treatment
Apixaban was the only NOAC to show a significantly lower risk of bleeding compared with warfarin INR 2.0–3.0 using all three outcome measures.
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
decreases
Apixaban 2.5 mg BD vs. Aspirin 100 mg OD | 0.28 | 0.82 | 0.34 | 0.71 | 0.55
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban 2.5 mg BD vs. Dabigatran 150 mg BD | 1.77 | 0.42 | 0.24 | 0.47 | 2.17
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban 2.5 mg BD vs. Rivaroxaban 20 mg OD | 1.01 | 0.23 | 0.03 | 0.28 | 1.16
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Apixaban 2.5 mg BD vs. Warfarin INR 2.0–3.0 | 2.37 | 0.23 | 0.13 | 0.26 | 1.93
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
increases
Aspirin 100 mg OD vs. Warfarin INR 2.0–3.0 | 8.60 | 0.29 | 0.38 | 0.37 | 3.55
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
decreases
Dabigatran 150 mg BD vs. Aspirin 100 mg OD | 0.16 | 1.93 | 1.43 | 1.50 | 0.25
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Dabigatran 150 mg BD vs. Warfarin INR 2.0–3.0 | 1.33 | 0.55 | 0.55 | 0.56 | 0.89
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
decreases
Rivaroxaban 20 mg OD vs. Aspirin 100 mg OD | 0.27 | 3.46 | 12.81 | 2.53 | 0.47
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban 20 mg OD vs. Dabigatran 150 mg BD | 1.76 | 1.80 | 9.00 | 1.68 | 1.85
PMID:27487187 · one of two readings recorded this
VTE and VTE-related death
no effect
Rivaroxaban 20 mg OD vs. Warfarin INR 2.0–3.0 | 2.34 | 0.99 | 4.89 | 0.93 | 1.67
PMID:27487187 · one of two readings recorded this
clinically significant bleeding (ISTH/TIMI composite) and MACE (MI, stroke, all-cause mortality composite) when NOACs (apixaban, rivaroxaban, dabigatran pooled) were added to single or dual antiplatelet therapy in ACS
NOAC plus DAPT: bleeding HR 2.24, 95% CI 1.75 to 2.87; MACE HR 0.86, 95% CI 0.78 to 0.93
Not recorded as a finding: another reason, stated per paper
Conversely, a modest reduction in MACE was achieved when NOAC was combined with DAPT (HR 0.86, 95% CI 0.78 to 0.93, p < 0.001); however, this strategy more than doubled the risk of bleeding (HR 2.24, 95% CI 1.75 to 2.87, p < 0.001).
PMID:29195825 · one of two readings recorded this
clinically significant bleeding
increases, p = 0.001
this strategy more than doubled the risk of bleeding (HR 2.24, 95% CI 1.75 to 2.87, p < 0.001)
PMID:29195825 · one of two readings recorded this
clinically significant bleeding
no effect, p = 0.31, n = 31574
In 31,574 patients, addition of NOAC to SAP did not increase the risk of clinically significant bleeding (HR 0.82, 95% CI 0.56 to 1.20, p = 0.31)
PMID:29195825 · one of two readings recorded this
clinically significant bleeding
decreases, p = 0.001
dabigatran plus SAP was a safer approach compared with control (HR 0.51, 95% CI 0.42 to 0.61, p < 0.001)
PMID:29195825 · one of two readings recorded this
MACE (myocardial infarction, stroke, all-cause mortality)
decreases, p = 0.001
a modest reduction in MACE was achieved when NOAC was combined with DAPT (HR 0.86, 95% CI 0.78 to 0.93, p < 0.001)
PMID:29195825 · one of two readings recorded this
MACE (myocardial infarction, stroke, all-cause mortality)
no effect, p = 0.1
also lacked the beneficial effect on MACE (HR 0.82, 95% CI 0.66 to 1.04, p = 0.10)
PMID:29195825 · one of two readings recorded this
MACE (myocardial infarction, stroke, all-cause mortality)
decreases
only rivaroxaban plus DAPT showed significant 17% reduction in MACE
PMID:29195825 · one of two readings recorded this
publication bias, Egger test, clinically significant bleeding
no effect, p = 0.75
Egger test did not highlight publication bias for clinically significant bleeding (2-tailed p = 0.75)
PMID:29195825 · one of two readings recorded this
publication bias, Egger test, MACE
no effect, p = 0.5
or MACE (2-tailed p = 0.50)
PMID:29195825 · one of two readings recorded this
bleeding events (major and clinically relevant non-major)
no effect, p = 0.05
Similar results were obtained in apixaban groups 4.09% (228/5570) compared with the control groups 4.64 (265/5755) that were all enoxaparin, indicating that no significant difference was observed in bleeding events of the two drugs (RR 0.85, 95% CI 0.71–1.02), P>0.05
PMID:30341244 · one of two readings recorded this
bleeding events (major and clinically relevant non-major)
no effect, p = 0.05
However, the effect was not significant (RR 0.69, 95% CI 0.42–1.12), P>0.05
PMID:30341244 · one of two readings recorded this
bleeding events (major and clinically relevant non-major)
no effect, p = 0.05
This result suggested that rivaroxaban may have a trend to increase the bleeding events compared with enoxaparin; however, the difference is not significant (RR 1.18, 95% CI 0.95–1.47), P>0.05
PMID:30341244 · one of two readings recorded this
composite of DVT, non-fatal pulmonary embolism and all-cause mortality, and bleeding events (major plus clinically relevant non-major), after hip or knee arthroplasty; apixaban vs enoxaparin
no effect, efficacy RR 0.59, 95% CI 0.34-1.02
Not recorded as a finding: the comparison was against another active treatment
The efficacy outcome of apixaban groups didn’t show significant difference compared with the control groups (RR 0.59, 95% CI 0.34-1.02), P>0.05.
PMID:30341244 · one of two readings recorded this
composite of DVT, non-fatal pulmonary embolism and all-cause mortality, and bleeding events (major plus clinically relevant non-major): apixaban vs enoxaparin after total hip or knee arthroplasty, pooled odds/risk ratios
no effect, apixaban vs enoxaparin efficacy composite RR 0.59, 95% CI 0.34-1.02
Not recorded as a finding: the comparison was against another active treatment
The efficacy outcome of apixaban groups didn’t show significant difference compared with the control groups (RR 0.59, 95% CI 0.34-1.02), P>0.05.
PMID:30341244 · one of two readings recorded this
primary efficacy composite (DVT, non-fatal pulmonary embolism, all-cause mortality)
no effect, p = 0.05
The efficacy outcome of apixaban groups didn’t show significant difference compared with the control groups (RR 0.59, 95% CI 0.34-1.02), P>0.05
PMID:30341244 · one of two readings recorded this
primary efficacy composite (DVT, non-fatal pulmonary embolism, all-cause mortality)
increases, p = 0.05
Results showed that events occurred in 11.03% patients (1919/17,397) of enoxaparin groups compared with 8.38% patients (1582/18,889) of the control groups, indicating that enoxaparin had a trend to increase the events (RR 1.56, 95% CI 1.20-2.04), P<0.05
PMID:30341244 · one of two readings recorded this
primary efficacy composite (DVT, non-fatal pulmonary embolism, all-cause mortality)
decreases, p = 0.0001
Total events occurred in 4.89% (509/10399) patients in rivaroxaban group compared with 9.55% (976/10221) patients in the control group, indicating rivaroxaban had a trend to decrease the events (RR 0.46, 95% CI 0.41-0.51), P<0.0001
PMID:30341244 · one of two readings recorded this
clinically relevant major bleeding
decreases, p = 0.01
Clinically relevant major bleeding occurred in 85 of 11 559 patients (0.74%) in the apixaban group and 350 of 33 909 patients (1.03%) in the rivaroxaban group (RR, 0.73; 95% CI, 0.58-0.93; P = .01)
PMID:31405948 · one of two readings recorded this
clinically relevant nonmajor bleeding
decreases, p = 0.01
Clinically relevant nonmajor bleeding occurred in 169 of 3417 patients (4.95%) in the apixaban group and 1094 of 12 475 patients (8.77%) in the rivaroxaban group (RR, 0.59; 95% CI, 0.50-0.70; P < .01)
PMID:31405948 · one of two readings recorded this
recurrent VTE within 6 months, clinically relevant major bleeding, clinically relevant non-major bleeding; apixaban vs rivaroxaban in acute VTE, real-world studies (abstract only)
no effect, recurrent VTE RR 0.89; 95% CI 0.67-1.19, p = 0.45
Not recorded as a finding: the comparison was against another active treatment
In an analysis involving 24 041 patients, recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45).
PMID:31405948 · one of two readings recorded this
recurrent VTE within 6 months, clinically relevant major bleeding, clinically relevant nonmajor bleeding: apixaban vs rivaroxaban in acute VTE, pooled risk ratios from real-world studies (abstract only)
recurrent VTE RR 0.89, 95% CI 0.67-1.19, p = 0.45
Not recorded as a finding: the comparison was against another active treatment
In an analysis involving 24 041 patients, recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45).
PMID:31405948 · one of two readings recorded this
recurrent VTE
no effect, p = 0.45
recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45)
PMID:31405948 · one of two readings recorded this
cost per LY gained
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Dabigatran (150 mg) | €1,959 | 0.008 | €244,079 | 0.022 | €90,398
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Edoxaban | €13 | 0.065 | €206 | 0.085 | €157
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Edoxaban | €186 | 0.065 | €2,884 | 0.085 | €2,193
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
Edoxaban | €385 | 0.038 | €10,243 | 0.055 | €6,951
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €1,518 | 0.262 | €5,787 | 0.269 | €5,636
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €1,390 | 0.246 | €5,648 | 0.249 | €5,580
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
cost per QALY gained (ICER)
VKA | €96 | 0.330 | €292 | 0.352 | €273
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Dabigatran (110mg) | - €2,692 | 0.177 | Dominant | 0.207 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Dabigatran (150 mg) | - €819 | 0.131 | Dominant | 0.157 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Dabigatran | - €3,612 | 0.310 | Dominant | 0.383 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Edoxaban | - €197 | 0.065 | Dominant | 0.085 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Rivaroxaban | - €1,027 | 0.101 | Dominant | 0.126 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
Rivaroxaban | - €1,625 | 0.124 | Dominant | 0.154 | Dominant
PMID:31527894 · one of two readings recorded this
incremental cost
increases
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
incremental cost
decreases
VKA | - €1,358 | 0.330 | Dominant | 0.352 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Dabigatran (110mg) | - €2,692 | 0.177 | Dominant | 0.207 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Dabigatran (150 mg) | - €819 | 0.131 | Dominant | 0.157 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Dabigatran | - €3,612 | 0.310 | Dominant | 0.383 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Edoxaban | - €197 | 0.065 | Dominant | 0.085 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Rivaroxaban | - €1,027 | 0.101 | Dominant | 0.126 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
Rivaroxaban | - €1,625 | 0.124 | Dominant | 0.154 | Dominant
PMID:31527894 · one of two readings recorded this
incremental LY
increases
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
incremental LY
increases
VKA | - €1,358 | 0.330 | Dominant | 0.352 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Dabigatran (110mg) | - €2,692 | 0.177 | Dominant | 0.207 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Dabigatran (150 mg) | - €819 | 0.131 | Dominant | 0.157 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Dabigatran | - €3,612 | 0.310 | Dominant | 0.383 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Edoxaban | - €197 | 0.065 | Dominant | 0.085 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Rivaroxaban | - €1,027 | 0.101 | Dominant | 0.126 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
Rivaroxaban | - €1,625 | 0.124 | Dominant | 0.154 | Dominant
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
VKA | €920 | 0.262 | €3,506 | 0.269 | €3,415
PMID:31527894 · one of two readings recorded this
incremental QALY
increases
VKA | - €1,358 | 0.330 | Dominant | 0.352 | Dominant
PMID:31527894 · one of two readings recorded this
probability of being the most cost-effective option at the WTP threshold
In NMA-based analysis, apixaban is the most cost-effective treatment option at the €20,000/QALY WTP threshold with 50%
PMID:31527894 · one of two readings recorded this
probability of being the most cost-effective option at the WTP threshold
In RWD-based analysis, similar results were found: apixaban is the most cost-effective treatment with 90%
PMID:31527894 · one of two readings recorded this
hemorrhagic stroke
no effect
A numerical difference was found that was suggestive of a potential benefit of apixaban in reducing the risk of hemorrhagic stroke in all 7 NMAs
PMID:31918558 · one of two readings recorded this
hemorrhagic stroke
no effect
Two RWE studies demonstrated a numerical, but nonsignificant difference in favor of apixaban (HR: 0.66, 95% CI: 0.16-2.78; HR: 0.87, 95% CI: 0.50-1.53), and one RWE study favored rivaroxaban (HR: 1.09, 95% CI: 0.89-1.33)
PMID:31918558 · one of two readings recorded this
hemorrhagic stroke
no effect
Two RWE studies demonstrated a numerical, but nonsignificant difference in favor of apixaban (HR: 0.66, 95% CI: 0.16-2.78; HR: 0.87, 95% CI: 0.50-1.53), and one RWE study favored rivaroxaban (HR: 1.09, 95% CI: 0.89-1.33)
PMID:31918558 · one of two readings recorded this
hemorrhagic stroke
no effect
Two RWE studies demonstrated a numerical, but nonsignificant difference in favor of apixaban (HR: 0.66, 95% CI: 0.16-2.78; HR: 0.87, 95% CI: 0.50-1.53), and one RWE study favored rivaroxaban (HR: 1.09, 95% CI: 0.89-1.33)
PMID:31918558 · one of two readings recorded this
ischemic stroke
no effect
No differences were observed for the outcome of ischemic stroke as indicated by the NMAs
PMID:31918558 · one of two readings recorded this
ischemic stroke
decreases
one reported a statistically significant difference in favor of apixaban (HR: 0.67, 95% CI: 0.49-0.92); the other reported a numerical difference in favor of rivaroxaban which was nonsignificant (HR: 1.27, 95% CI: 0.73-2.23)
PMID:31918558 · one of two readings recorded this
ischemic stroke
no effect
one reported a statistically significant difference in favor of apixaban (HR: 0.67, 95% CI: 0.49-0.92); the other reported a numerical difference in favor of rivaroxaban which was nonsignificant (HR: 1.27, 95% CI: 0.73-2.23)
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
These demonstrated results similar to the main analysis (apixaban 2.5 mg or 5 mg) for the outcome of major bleeding (HR: 0.41, 95% CI: 0.29-0.56 and 0.56, 95% CI: 0.41-0.78, respectively)
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
These demonstrated results similar to the main analysis (apixaban 2.5 mg or 5 mg) for the outcome of major bleeding (HR: 0.41, 95% CI: 0.29-0.56 and 0.56, 95% CI: 0.41-0.78, respectively)
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
All 5 RWE studies reported major bleeding, with all demonstrating a statistically significant advantage in favor of apixaban
PMID:31918558 · one of two readings recorded this
major bleeding
decreases
Sixteen of the 21 NMAs reported apixaban had a significantly lower risk of major bleeding compared with rivaroxaban
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism, ischemic and hemorrhagic stroke, ISTH major bleeding: apixaban vs rivaroxaban in nonvalvular atrial fibrillation, narrated across network meta-analyses and real-world cohort studies, no pooling
decreases, major bleeding, apixaban vs rivaroxaban, NMA HR range 0.51-0.74
Not recorded as a finding: the comparison was against another active treatment
Sixteen of the 21 NMAs reported apixaban had a significantly lower risk of major bleeding compared with rivaroxaban, with the other 5 demonstrating a numerical difference in favor of apixaban (HR: 0.51-0.74; OR: 0.19-0.71; RR: 0.68-0.80; Figure 3).
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
no effect
Results from 15 of 21 NMAs examining stroke/systemic embolism showed that apixaban and rivaroxaban had a comparable efficacy profile in terms of preventing the stroke/systemic embolism risk
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
decreases
one study, including only AF patients >65 years of age, demonstrated a statistically significant advantage for apixaban compared to rivaroxaban in the reduction of stroke/systemic embolism risk (HR: 0.72, 95% CI: 0.55-0.95)
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
no effect
favored rivaroxaban in a dose-adjusting sensitivity analysis that included both the reduced (2.5 mg) and standard dose (main analyses; HR: 1.11, 95% CI: 0.68-1.81)
PMID:31918558 · one of two readings recorded this
stroke/systemic embolism
no effect
The second study found comparable results between the 2 interventions (HR: 1.05, 95% CI: 0.64-1.72)
PMID:31918558 · one of two readings recorded this
all-cause mortality
no effect, p = 0.33
All-cause mortality | 1.12 [0.89–1.40] |.33
PMID:33761699 · one of two readings recorded this
any bleeding event
increases, p = 0.0007
Any bleeding event | 1.91 [1.31–2.77] |.0007
PMID:33761699 · one of two readings recorded this
fatal bleeding
no effect, p = 0.11
Fatal bleeding | 10.96 [0.61–198.3] |.11
PMID:33761699 · one of two readings recorded this
GUSTO defined severe bleeding
increases, p = 0.01
GUSTO defined severe bleeding | 3.00 [1.56–5.78] |.01
PMID:33761699 · one of two readings recorded this
ISTH defined minor bleeding
no effect, p = 0.08
ISTH defined minor bleeding | 2.33 [0.91–5.96] |.08
PMID:33761699 · one of two readings recorded this
ISTH major bleeding
increases, p = 0.00001
ISTH major bleeding | 2.49 [1.80–3.45] |.00001
PMID:33761699 · one of two readings recorded this
major adverse cardiac events (MACEs)
no effect, p = 0.67
MACEs | 0.96 [0.82–1.14] |.67
PMID:33761699 · one of two readings recorded this
myocardial infarction (MI)
no effect, p = 0.44
MI | 0.92 [0.75–1.13] |.44
PMID:33761699 · one of two readings recorded this
stent thrombosis
no effect, p = 0.15
Stent thrombosis | 0.72 [0.47–1.12] |.15
PMID:33761699 · one of two readings recorded this
stroke
no effect, p = 0.22
Stroke | 0.73 [0.44–1.20] |.22
PMID:33761699 · one of two readings recorded this
TIMI defined major bleeding
increases, p = 0.0008
TIMI defined major bleeding | 2.45 [1.45–4.12] |.0008
PMID:33761699 · one of two readings recorded this
TIMI defined minor bleeding
increases, p = 0.0002
TIMI defined minor bleeding | 3.12 [1.71–5.70] |.0002
PMID:33761699 · one of two readings recorded this
all-cause mortality
no effect
Meta-analysis of studies assessing API did not demonstrate significant differences versus SoC in either of the feasible scenarios but point estimates in favor of API
PMID:35801133 · one of two readings recorded this
all-cause mortality
decreases
A meta-analysis of all studies revealed that RIV was associated with a significantly lower risk of death compared with SoC (HR = 0.56 (0.39, 0.80))
PMID:35801133 · one of two readings recorded this

The whole record — 259 rows